68Ga-PSMA-11

Phase 3

Telix Pharmaceuticals Ltd (TLX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

TLXPhase 3$3.8B

68Ga-PSMA-11 Phase 3 Est. Readout

68Ga-PSMA-11• Biochemical Recurrence of Malignant Neoplasm of Prostate338

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Biochemical Recurrence of Malignant Neoplasm of Prostate

View Full Landscape

Drug Information

Target Indication

Biochemical Recurrence of Malignant Neoplasm of Prostate

Clinical Trial

NCT05847348

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TLX

Telix Pharmaceuticals Ltd

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

89Zr-TLX250 PET/CTPhase 3

Clear Cell Renal Cell Carcinoma

177Lu-TLX591Phase 3

Metastatic Castration-resistant Prostate Cancer

Standard of CarePhase 3

Metastatic Prostate Cancer

PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CCPhase 2

Prostate Cancer

Zirconium Zr 89 GirentuximabPhase 2

Clear Cell Renal Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts